Literature DB >> 31018581

Limited Knowledge of Chronic Kidney Disease among Type 2 Diabetes Mellitus Patients in India.

Salman Hussain1, Anwar Habib2, Abul Kalam Najmi3.   

Abstract

Diabetes and hypertension are the two major causes of chronic kidney disease (CKD). Epidemiological studies have found poor knowledge about the CKD among the general population. Hence, this study aimed to assess the awareness of CKD among type 2 diabetes mellitus (T2DM) patients in India. Patients with confirmed T2DM were included in the study. Patients receiving dialysis or with a history of a kidney transplant were excluded. A validated questionnaire was used to assess knowledge about CKD. Demographic characteristics were presented using descriptive statistics and trends in groups were calculated using the chi-square test. Statistical analysis was performed using SAS v9.4. A total of 323 patients completed the study. The mean age of the patients was 56 ± 11.25 years, and 51.7% were female. Only 33.43% of the patients correctly identified diabetes and hypertension as risk factors for CKD, while 44.27% were aware of the kidney's function. Statistically significant associations were observed between kidney disease knowledge and education status (p = 0.004), socioeconomic status (p = 0.000), and income status (p = 0.003). No association was observed between the knowledge about CKD and age, gender, hypertension stages, CKD stages, duration of diabetes as well as hypertension and co-morbidities. Based on the results of this study, we found poor knowledge of CKD among Indian T2DM patients. The government should start a CKD awareness programme to deal with this rising co-morbid condition.

Entities:  

Keywords:  India; chronic kidney disease; diabetes; diabetic kidney disease; epidemiology; hypertension; public health

Mesh:

Year:  2019        PMID: 31018581      PMCID: PMC6518175          DOI: 10.3390/ijerph16081443

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


1. Introduction

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a common microvascular complication of type 2 diabetes mellitus (T2DM). DKD is considered a major public health problem for both the patient and the healthcare system. Diabetes and hypertension are two major risk factors of chronic kidney disease (CKD) [1]. Even pre-hypertension is associated with an increased risk of CKD, with a relative risk of 1.28 (95% CI: 1.13 to 1.44) [2]. Albuminuria and proteinuria are hallmarks for CKD, which is characterized by a decline in renal function [3,4]. Diabetes and hypertension are also the most common causes of end-stage renal failure, accounting for nearly 50% of cases [5,6,7]. In the United States (US), diabetes and hypertension are the leading causes of kidney failure in CKD patients [8]. CKD has high global prevalence, with rates reported between 11% to 13% [9]. The Start India Project, which assessed the prevalence of CKD among diabetic patients, has estimated that more than 40% of T2DM patients have CKD. Likewise, one in five hypertensive subjects has CKD [10]. According to the 2010 Global Burden of Disease study, diabetes and CKD were ranked 9th and 18th among the listed causes of overall global mortality [11]. DKD was also associated with higher mortality, morbidity, and healthcare expenditure [12,13], imparting high economic burden on DKD patients [14]. Real world studies have also suggested a significant and incremental increase in the economic burden for DKD patients [14,15]. A retrospective cohort study found that T2DM patients with co-morbid stage-4 CKD incur yearly costs of USD 33,162 for their treatment [16]. In another retrospective observational study, DKD was found to be significantly associated with higher costs of treatment, healthcare resource use, and risk of disease progression [17]. According to a report from the National Health Service (NHS), treating kidney disease costs more than skin, lung, and breast cancer combined [18]. The economic burden due to CKD can be reduced if patients are diagnosed at an early stage. In low- and middle-income countries (LMICs), the majority of the patients generally only become aware of their CKD status when they reach the end-stage of kidney failure and require dialysis [19]. Furthermore, due to the absence of appropriate healthcare coverage and limited access to renal replacement therapy, the treatment of end-stage renal disease (ESRD) becomes unaffordable in LMICs, and patients are bound to pay out-of-pocket [20]. Timely diagnosis and treatment are the most cost-effective and clinically appropriate public health strategies to deal with this condition. Early identification and treatments for DKD have been shown to slow, stop, or even reverse the progress of the disease and the decline of kidney function [21,22]. Yet the majority of CKD cases are not identified early. Limited knowledge of CKD is the main barrier to the early diagnosis and prevention of disease progression [23]. Several epidemiological studies have reported about the limited knowledge of CKD among the general public [24,25]. A global cross-sectional study done in six regions (Eastern Asia, Southern Asia, Middle East, Africa, Eastern Europe, and Latin America) found only 6% of the public to be aware of CKD [26]. Similarly, the data provided by the Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) revealed that only 9% of the DKD patients were aware of their CKD status [27]. A study by Chow et al. found there to be poor knowledge of CKD in the general public and suggested future studies in population of high-risk individuals [24]. In a resource-limited country like India, where there are only 6.49 physicians for every 10,000 people [28] and the cost of dialysis is unaffordable [19], awareness of the disease is of paramount importance and is considered to be the first step toward prevention. Therefore, this study aimed to evaluate the knowledge of CKD among T2DM patients in India.

2. Methodology

2.1. Study Setting

This cross-sectional study was conducted at the out-patient department of endocrinology, at Hakeem Abdul Hameed Centenary (HAHC) Hospital, Jamia Hamdard, New Delhi, India. The study period was from April 2017–May 2018. Before the initiation of the study, the study protocol was approved by the Jamia Hamdard Institutional Ethics Committee (JHIEC-2017-04/17), India. The study was conducted in full compliance with the Declaration of Helsinki guidelines [29] and written in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting a cross-sectional study [30]. Written informed consent was provided voluntarily by the participants. Participants were assured of their confidentiality and the anonymity of their identity.

2.2. Study Population

Patient selection was carried out on the basis of pre-defined inclusion and exclusion criteria. Only participants that fulfilled all the following criteria were included in the study: (a) willingness to participate in the study by providing signed informed consent form; (b) patients aged 18 years or above of either sex; (c) patients who had confirmed T2DM as per their medical records. Participants were excluded from the study if they were receiving dialysis or had a history of a kidney transplant. Patients with incomplete interview information were also excluded. Patients’ demographic characteristics like age, sex, marital status, substance use (smoking, drinking), and family history were recorded in the case record form. We used modified Kuppuswamy’s socioeconomic scale to assess the economic status of the patients. According to this scale, socioeconomic status was divided into five subscales (upper, upper middle, lower middle, upper lower, and lower) on the basis of occupation, education, and family income. The majority of the patients fell into two categories, lower or lower middle class, so the patients were categorized into two classes (i.e., lower class or middle class).

2.3. Questionnaire Used

The questionnaire used to assess the CKD awareness was adopted from Chow et al. [24]. The questionnaire consisted of seven questions covering aspects of anatomy (number of kidneys needed to lead a normal life), physiology (the function of a kidney), etiology (risk factors of CKD), presentation (symptoms of CKD, progression), resources availability, and treatment (please refer to the supplementary file for the questionnaire). Every correct answer was allocated one point, so that patients could score a maximum of seven points or a minimum of zero point. Patients were considered to have good knowledge if they scored ≥4 points and poor knowledge if they scored <4 points.

2.4. Clinical and Laboratory Analysis

Anthropometric parameters and blood pressure were recorded by the trained nurse personnel. Blood pressure was measured using Richter auscultatory sphygmomanometers at two times: one at 5 min of rest and another at sitting position. Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded. Patients’ blood pressure records were also reviewed for an accurate reflection of hypertension stage. Patients were classified as hypertensive if the mean SBP was ≥140 mmHg and DBP was ≥90 mmHg or if they had been previously prescribed antihypertensive medication. Patients were further categorized as prehypertensive (SBP 120–139 mmHg or DBP 80–89 mmHg), stage-I hypertensive (SBP 140–159 mmHg or DBP 90–99 mmHg), and stage II hypertensive (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) [31]. Similarly, T2DM was defined on the basis of their medical record or fasting plasma glucose and/or glycated hemoglobin (HbA1c) level or as per the American Diabetes Association (ADA) guidelines (random blood sugar ≥ 200 mg/dL) [32]. To assure the accurate reflection of glycemic control, we also reviewed the patients’ HbA1c records. HbA1c level below 7 was considered a good glycemic control, and HbA1c ≥ 7 was considered a poor glycemic control. CKD was defined on the basis of kidney function, as determined by means of estimated glomerular filtration rate (eGFR). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate the eGFR (mL/min/1.73 m2) [33]. The National Kidney Foundation (NKF) classified CKD into six stages based on eGFR, where stage I refers to eGFR ≥ 90, stage II refers to eGFR 60–89, stage IIIa refers to eGFR 45–59, stage IIIb refers to eGFR 30–44, stage IV refers to eGFR 15–29, and stage V refers to eGFR < 15 [34]. Due to the small number of patients in CKD stage IIIa, IIIb, and IV, we included these classifications together under CKD stage III. The status of co-morbidities and duration of diabetes and hypertension were confirmed by physician, patients’ previous medical records, and current prescription. Literacy was self-reported by the patient. Blood samples (5 mL) were collected for the routine test. The HbA1c test was performed by using a fully automated HPLC using a BIORAD testing system. Serum creatinine was determined by a modified Jaffe colorimetric method using a fully automated Siemens adiva-1800 chemistry analyzer (Siemens Healthcare Pvt Ltd., Mumbai, India). Blood glucose levels were determined by using a fully automated Roche Cobas 6000 analyzer (Roche, Mannheim, Germany). The entire tests were performed in the central pathology lab of Hamdard Institute of Medical Sciences and Research.

2.5. Statistical Analysis

Demographic characteristics were presented using descriptive statistics. Categorical variables were presented by frequency and percentages. Differences and association were computed using the chi-square test and multiple logistic regression. We considered good knowledge (≥4 scores) and poor knowledge (<4 scores) as the dependent dichotomous variable and associations were computed using the chi-square test. Similarly, we considered correct and incorrect responses of every question (domains) as the dependent dichotomous variable and associations with the demographic characteristics and clinical parameters were calculated using the chi-square test. A p value < 0.05 was considered statistically significant. All the statistical analyses were performed using SAS v9.4 (SAS Institute Inc: Cary, NC, USA).

3. Results

A total of 365 patients participated in the study, of which 42 were excluded, as they did not fulfill the inclusion criteria. The mean ± SD age of patients was 56 ± 11.25 years, and 51.7% were female. The majority (96.3%) was married and not covered by health schemes or health insurance and bound to pay out-of-pocket for the treatment. More than three-fourth of patients (77.7%) was of lower socioeconomic status and 63.5% were educated. Mean ± SD duration of diabetes was 10 ± 4.39 years and approximately 43.3% of the patients had a family history of diabetes. CKD stage III was prevalent in 34.4% (eGFR < 60 mL/min/1.73 m2) of patients, while 23.5% and 17.3% of patients had hypertension stage I and stage II, respectively. Demographic characteristics are presented in Table 1.
Table 1

Background characteristics of the patients.

VariablesMaleFemaleTotalp Value
Age groups >0.999
≥5093 (59.6%)99 (59.3%)192 (59.4%)
<5063 (40.4%)68 (40.7%)131 (40.6%)
Marital Status >0.999
Married150 (96.2%)161 (96.4%)311 (96.3%)
Unmarried6 (3.85%)6 (3.59%)12 (3.72%)
Family History of Diabetes 0.8223
Yes69 (44.2%)71 (42.5%)140 (43.3%)
No87 (55.8%)96 (57.5%)183 (56.7%)
Substance Use 0.0459
Yes43 (27.6%)30 (18.0%)73 (22.6%)
No113 (72.4%)137 (82.0%)250 (77.4%)
Education 0.0077
Literate111 (71.2%)94 (56.3%)205 (63.5%)
Illiterate45 (28.8%)73 (43.7%)118 (36.5%)
Occupation 0.0308
Employed98 (62.8%)124 (74.3%)222 (68.7%)
Unemployed58 (37.2%)43 (25.7%)101 (31.3%)
Socioeconomic Status 0.0324
Middle43 (27.6%)29 (17.4%)72 (22.3%)
Lower113 (72.4%)138 (82.6%)251 (77.7%)
CKD Stage 0.3724
Stage III48 (30.8%)63 (37.7%)111 (34.4%)
Stage II65 (41.7%)66 (39.5%)131 (40.6%)
Stage I43 (27.6%)38 (22.8%)81 (25.1%)
HTN Stage 0.6244
Stage I HTN40 (25.6%)36 (21.6%)76 (23.5%)
Stage II HTN23 (14.7%)33 (19.8%)56 (17.3%)
Prehypertension43 (27.6%)46 (27.5%)89 (27.6%)
Normal50 (32.1%)52 (31.1%)102 (31.6%)
BMI Categories 0.6529
Overweight61 (39.1%)59 (35.3%)120 (37.2%)
Obese32 (20.5%)41 (24.6%)73 (22.6%)
Normal63 (40.4%)67 (40.1%)130 (40.2%)
Co-morbidities 0.6431
Yes53 (34.0%)61 (36.5%)114 (35.3%)
No103 (66.0%)106 (63.5%)209 (64.7%)
Duration of diabetes 0.3743
Less than 10 years79 (50.6%)89 (53.3%)168 (52.0%)
More than 10 years77 (49.4%)78 (46.7%)155 (48.0%)
Duration of HTN
Less than 5 years44 (63.76%)37 (58.73%)81 (61.36%)0.5942
More than 5 years25 (36.23%)26 (41.26%)51 (38.63%)

CKD: Chronic Kidney Disease; HTN: Hypertension; BMI: Body Mass Index.

3.1. Patient’s Knowledge of CKD

Amongst seven domains of CKD knowledge, 118 patients (36.53%) correctly answered the anatomy part of the questionnaire that only one kidney is required to live a normal life. Less than half of the study population (44.27%) was aware that the filtration of waste products in the blood is the function of the kidney. More than three-fourth of the respondents (77.08%) correctly identified the risk factors of CKD in which only one-third (33.43%) of the respondents were aware of diabetes and hypertension as risk factors. Only 6.5% correctly identified hypertension, diabetes, and inherited condition as risk factors for the development of CKD. While 29.72% of the patients correctly identified symptoms of early kidney disease that might progress to kidney failure, only 4.95% of patients were aware that kidney disease could present without any symptoms. Likewise, a similar percentage of patients correctly identified that medications cannot cure CKD. Only 13.93% of patients were aware that dialysis treatment can be carried out both in a dialysis center and at home. Figure 1 shows the percentages of patients who correctly answered the questions.
Figure 1

Percentage of patients with correct responses to the administered questionnaire.

Only 21.36% of respondents were found to have good knowledge (≥4 scores) of CKD, and the remaining had poor knowledge (<4 scores) of CKD (Table 2). Respondents who were literate, had a monthly family income more than 20,000 INR (Indian National Rupees), and belong to the middle class were found to have significantly good knowledge of CKD (all p < 0.05). No significant difference in knowledge score was observed among respondents stratified according to CKD stages, hypertension stages, BMI, gender, co-morbidities, family history, and duration of diabetes and hypertension (all p > 0.05).
Table 2

Knowledge scores among the patients stratified on the basis of demographic and clinical characteristics.

VariablesLess than 4 Correct AnswersAt least 4 Correct AnswersTotalp Value
Age Groups 0.5832
≥50153 (60.2%)39 (56.5%)192 (59.4%)
<50101 (39.8%)30 (43.5%)131 (40.6%)
Gender 0.2231
Female136 (53.5%)31 (44.9%)167 (51.7%)
Male118 (46.5%)38 (55.1%)156 (48.3%)
Family History of Diabetes 0.1018
Yes104 (40.9%)36 (52.2%)140 (43.3%)
No150 (59.1%)33 (47.8%)183 (56.7%)
Substance Use 0.8724
Yes57 (22.4%)16 (23.2%)73 (22.6%)
No197 (77.6%)53 (76.8%)250 (77.4%)
Education 0.004
Literate151 (59.44%)54 (78.26%)205 (63.5%)
Illiterate103 (40.56%)15 (21.74%)118 (36.5%)
Occupation 0.0783
Employed181 (71.3%)41 (59.4%)222 (68.7%)
Unemployed73 (28.7%)28 (40.6%)101 (31.3%)
Socioeconomic Status 0.0003
Middle45 (17.7%)27 (39.1%)72 (22.3%)
Lower209 (82.3%)42 (60.9%)251 (77.7%)
Monthly Family Income 0.0034
More than 20,000 INR34 (13.4%)20 (29.0%)54 (16.7%)
Less than 20,000 INR220 (86.6%)49 (71.0%)269 (83.3%)
CKD Stages 0.5453
Stage III89 (35.0%)22 (31.9%)111 (34.4%)
Stage II99 (39.0%)32 (46.4%)131 (40.6%)
Stage I66 (26.0%)15 (21.7%)81 (25.1%)
HTN Stages 0.4704
Stage I HTN63 (24.8%)13 (18.8%)76 (23.5%)
Stage II HTN40 (15.7%)16 (23.2%)56 (17.3%)
Prehypertension70 (27.6%)19 (27.5%)89 (27.6%)
Normal81 (31.9%)21 (30.4%)102 (31.6%)
Glycemic Control 0.1321
Poor (HbA1c ≥ 7)187 (73.6%)44 (63.8%)231 (71.5%)
Good (HbA1c < 7)67 (26.4%)25 (36.2%)92 (28.5%)
BMI Categories 0.5314
Overweight97 (38.2%)23 (33.3%)120 (37.2%)
Obese59 (23.2%)14 (20.3%)73 (22.6%)
Normal98 (38.6%)32 (46.4%)130 (40.2%)
Co-morbidities 0.4791
Yes87 (34.3%)27 (39.1%)114 (35.3%)
No167 (65.7%)42 (60.9%)209 (64.7%)
Duration of Diabetes 0.3418
Less than 10 years136 (53.5%)32 (46.4%)168 (52.0%)
More than 10 years118 (46.5%)37 (53.6%)155 (48.0%)
Duration of HTN
Less than 5 years66 (62.85%)15 (55.55%)81 (61.36%)0.5123
More than 5 years39 (37.15%)12 (44.45%)51 (38.63%)

INR: Indian National Rupees; CKD: Chronic Kidney Disease; HbA1c: Glycated Hemoglobin; HTN: Hypertension; BMI: Body Mass Index.

3.2. Factors Influencing CKD knowledge

Being older (≥50 years), female gender, substance use (smoking, drinking), and occupation were non-significantly associated with CKD knowledge in all of the seven domains of the questionnaire. Patients who had a family history of diabetes were more likely to have a higher knowledge of CKD in all the domains except the treatment domain. Patients belonging to the middle class were found to have a significantly higher knowledge of CKD in almost every domain of the CKD questionnaire (p < 0.05). Similarly, patients who had a monthly family income more than 20,000 INR were found to have a significantly higher knowledge of CKD (p < 0.05). Poor glycemic control patients were found to have a higher knowledge of the anatomy-related part of the questionnaire, with an odds ratio of 1.71 (95% CI: 1.04 to 2.80) as compared to good glycemic control patients (Table 3 and Table 4). CKD stage II and III patients had significantly higher knowledge in the physiology and disease progression parts of the questionnaire, respectively (p < 0.05), in comparison to the stage I CKD patients. A detailed description of the results is presented in Table 3 and Table 4. Multiple logistic regression analysis reveals that patients who were literate (adjusted odds ratio (AOR) 1.78 (95% CI: 1.30–2.36), p = 0.02) and had a higher family income (AOR 2.26 (95% CI: 1.66–3.14), p = 0.04) was found to have significantly good knowledge of CKD.
Table 3

Association between different domains of knowledge and demographic characteristics.

VariablesC_Q1 (Anatomy)IC_Q1 (Anatomy)Odds RatioC_Q2 (Physiology)IC_Q2 (Physiology)Odds RatioC_Q3 (Etiology)IC_Q3 (Etiology)Odds Ratio
Age Groups
≥5066 (20.4%)126 (39.0%)0.796(0.503, 1.260)80 (24.8%)112 (34.7%)0.771(0.493, 1.205)154 (47.7%)38 (11.8%)1.536(0.911, 2.590)
<5052 (16.1%)79 (24.5%)Reference63 (19.5%)68 (21.1%)Reference95 (29.4%)36 (11.1%)Reference
Gender
Female60 (18.5%)107 (33.1%)0.947(0.602, 1.491)70 (21.7%)97 (30.0%)0.821(0.529, 1.274)126 (39.0%)41 (12.7%)0.825(0.490, 1.389)
Male58 (18.0%)98 (30.3%)Reference73 (22.6%)83 (25.7%)Reference123 (38.1%)33 (10.2%)Reference
Family History of Diabetes
Yes56 (17.3%)84 (26.0%)1.301(0.825, 2.053)72 (22.3%)68 (21.1%)1.670(1.070, 2.607)115 (35.6%)25 (7.74%)1.682(0.978, 2.893)
No62 (19.2%)121 (37.5%)Reference71 (22.0%)112 (34.7%)Reference134 (41.5%)49 (15.2%)Reference
Substance Use
Yes30 (9.29%)43 (13.3%)1.284(0.753, 2.190)34 (10.5%)39 (12.1%)1.128(0.668, 1.903)61 (18.9%)12 (3.72%)1.676(0.847, 3.317)
No88 (27.2%)162 (50.2%)Reference109 (33.7%)141 (43.7%)Reference188 (58.2%)62 (19.2%)Reference
Education
Literate74 (22.9%)131 (40.6%)0.950(0.594, 1.519)87 (26.9%)118 (36.5%)0.816(0.518, 1.287)162 (50.2%)43 (13.3%)1.342(0.790, 2.281)
Illiterate44 (13.6%)74 (22.9%)Reference56 (17.3%)62 (19.2%)Reference87 (26.9%)31 (9.60%)Reference
Occupation
Employed76 (23.5%)146 (45.2%)0.731(0.451, 1.185)92 (28.5%)130 (40.2%)0.694(0.432, 1.113)170 (52.6%)52 (16.1%)0.910(0.517, 1.603)
Unemployed42 (13.0%)59 (18.3%)Reference51 (15.8%)50 (15.5%)Reference79 (24.5%)22 (6.81%)Reference
Socioeconomic Status
Middle34 (10.5%)38 (11.8%) 1.779 (1.045, 3.028) * 45 (13.9%)27 (8.36%) 2.602 (1.516, 4.467) ** 63 (19.5%)9 (2.79%) 2.446 (1.152, 5.196) *
Lower84 (26.0%)167 (51.7%)Reference98 (30.3%)153 (47.4%)Reference186 (57.6%)65 (20.1%)Reference
Family Income
More than 20,000 INR(monthly)27 (8.36%)27 (8.36%) 1.956 (1.084, 3.529) * 32 (9.91%)22 (6.81%) 2.070 (1.142, 3.752) * 47 (14.6%)7 (2.17%) 2.227 (0.961, 5.162) *
Less than 20,000 INR(monthly)91 (28.2%)178 (55.1%)Reference111 (34.4%)158 (48.9%)Reference202 (62.5%)67 (20.7%)Reference
CKD Stage
Stage III36 (11.1%)75 (23.2%)0.861(0.471, 1.574)46 (14.2%)65 (20.1%)1.269(0.703, 2.291)86 (26.6%)25 (7.74%)1.536(0.803, 2.937)
Stage II53 (16.4%)78 (24.1%)1.218(0.687, 2.160)68 (21.1%)63 (19.5%) 1.935 (1.096, 3.419) * 107 (33.1%)24 (7.43%)1.990(1.042, 3.800)
Stage I29 (8.98%)52 (16.1%)Reference29 (8.98%)52 (16.1%)Reference56 (17.3%)25 (7.74%)Reference
HTN Stage
Stage I HTN24 (7.43%)52 (16.1%)0.659(0.353, 1.231)31 (9.60%)45 (13.9%)0.908(0.497, 1.659)46 (14.2%)30 (9.29%)0.307(0.153, 0.614) **
Stage II HTN23 (7.12%)33 (10.2%)0.996(0.513, 1.931)34 (10.5%)22 (6.81%) 2.037 (1.049, 3.958) ** 44 (13.6%)12 (3.72%)0.733(0.322, 1.671)
Prehypertension29 (8.98%)60 (18.6%)0.690(0.381, 1.250)34 (10.5%)55 (17.0%)0.815(0.456, 1.455)74 (22.9%)15 (4.64%)0.987(0.461, 2.112)
Normal42 (13.0%)60 (18.6%)Reference44 (13.6%)58 (18.0%)Reference85 (26.3%)17 (5.26%)Reference
BMI Categories
Overweight39 (12.1%)81 (25.1%)0.770(0.458, 1.296)54 (16.7%)66 (20.4%)1.152(0.698, 1.900)98 (30.3%)22 (6.81%)1.840(1.013, 3.343)
Obese29 (8.98%)44 (13.6%)1.055(0.586, 1.897)35 (10.8%)38 (11.8%)1.296(0.728, 2.308)59 (18.3%)14 (4.33%)1.741(0.869, 3.486)
Normal50 (15.5%)80 (24.8%)Reference54 (16.7%)76 (23.5%)Reference92 (28.5%)38 (11.8%)Reference
Co-morbidities
Yes43 (13.3%)71 (22.0%)1.082(0.675, 1.736)51 (15.8%)63 (19.5%)1.030(0.650, 1.630)87 (26.9%)27 (8.36%)0.935(0.545, 1.605)
No75 (23.2%)134 (41.5%)Reference92 (28.5%)117 (36.2%)Reference162 (50.2%)47 (14.6%)Reference
Duration of Diabetes
More than 10 years56 (17.3%)99 (30.7%)0.967(0.615, 1.522)68 (21.1%)87 (26.9%)0.969(0.625, 1.504)117 (36.2%)38 (11.8%)0.840(0.500, 1.412)
Less than 10 years62 (19.2%)106 (32.8%)Reference75 (23.2%)93 (28.8%)Reference132 (40.9%)36 (11.1%)Reference
Glycemic Control
Poor (HbA1c ≥ 7)76 (23.5%)155 (48.0%) 1.713 (1.046, 2.806) * 95 (29.4%)136 (42.1%)1.562(0.961, 2.539)174 (53.9%)57 (17.6%)1.445(0.789, 2.648)
Good (HbA1c < 7)42 (13.0%)50 (15.5%)Reference48 (14.9%)44 (13.6%)Reference75 (23.2%)17 (5.26%)Reference
Duration of HTN #
More than 5 years22 (16.66%)29 (21.97%)1.16 (0.57, 2.36)28 (21.21%)23 (17.42%)1.13(0.55, 2.28)39 (29.54%)12 (9.09%)1.28(0.57, 2.88)
Less than 5 years32 (24.24%)49 (37.12%)Reference42 (31.81%)39 (29.54%)Reference58 (43.94%)23 (17.42%)Reference

C: Correct response; IC: Incorrect response; INR: Indian National Rupees; CKD: Chronic Kidney Disease; HTN: Hypertension; BMI: Body Mass Index. Bold data represents significant value. * Represents significant findings (p < 0.05); ** Represents significant findings (p <0.001); # Analysis based on patients belongs to stage I and stage II HTN class only.

Table 4

Association between different domains of knowledge and demographic characteristics (continued).

VariablesC_Q4 (Symptoms)IC_Q4 (Symptoms)Odds RatioC_Q5 (Progression)IC_Q5 (Progression)Odds RatioC_Q6 (Treatment)IC_Q6 (Treatment)Odds RatioC_Q7 (Resource)IC_Q7 (Resource)Odds Ratio
Age Groups
≥5054 (16.7%)138 (42.7%)0.829(0.511, 1.344)23 (7.12%)169 (52.3%)0.802(0.418, 1.541)23 (7.12%)169 (52.3%)0.674(0.358, 1.269)26 (8.05%)166 (51.4%)0.664(0.364, 1.211)
<5042 (13.0%)89 (27.6%)Reference19 (5.88%)112 (34.7%)Reference22 (6.81%)109 (33.7%)Reference25 (7.74%)106 (32.8%)Reference
Gender
Female46 (14.2%)121 (37.5%)0.806(0.500, 1.300)26 (8.05%)141 (43.7%)1.613(0.829, 3.137)20 (6.19%)147 (45.5%)0.713(0.378, 1.343)25 (7.74%)142 (44.0%)0.880(0.484, 1.601)
Male50 (15.5%)106 (32.8%)Reference16 (4.95%)140 (43.3%)Reference25 (7.74%)131 (40.6%)Reference26 (8.05%)130 (40.2%)Reference
Family History of Diabetes
Yes48 (14.9%)92 (28.5%)1.467(0.908, 2.371)25 (7.74%)115 (35.6%) 2.123 (1.097, 4.109) * 21 (6.50%)119 (36.8%)1.169(0.621, 2.200)22 (6.81%)118 (36.5%)0.990(0.541, 1.811)
No48 (14.9%)135 (41.8%)Reference17 (5.26%)166 (51.4%)Reference24 (7.43%)159 (49.2%)Reference29 (8.98%)154 (47.7%)Reference
Substance Use
Yes22 (6.81%)51 (15.8%)1.026(0.581, 1.812)13 (4.02%)60 (18.6%)1.651(0.809, 3.371)6 (1.86%)67 (20.7%)0.485(0.197, 1.195)10 (3.10%)63 (19.5%)0.809(0.384, 1.707)
No74 (22.9%)176 (54.5%)Reference29 (8.98%)221 (68.4%)Reference39 (12.1%)211 (65.3%)Reference41 (12.7%)209 (64.7%)Reference
Education
Literate64 (19.8%)141 (43.7%)1.220(0.738, 2.015)27 (8.36%)178 (55.1%)1.041(0.530, 2.048)28 (8.67%)177 (54.8%)0.940(0.490, 1.801)28 (8.67%)177 (54.8%)0.653(0.357, 1.197)
Illiterate32 (9.91%)86 (26.6%)Reference15 (4.64%)103 (31.9%)Reference17 (5.26%)101 (31.3%)Reference23 (7.12%)95 (29.4%)Reference
Occupation
Employed61 (18.9%)161 (49.8%)0.714(0.431, 1.184)25 (7.74%)197 (61.0%)0.627(0.322, 1.222)33 (10.2%)189 (58.5%)1.295(0.638, 2.626)30 (9.29%)192 (59.4%)0.595(0.322, 1.102)
Unemployed35 (10.8%)66 (20.4%)Reference17 (5.26%)84 (26.0%)Reference12 (3.72%)89 (27.6%)Reference21 (6.50%)80 (24.8%)Reference
Socioeconomic Status
Middle31 (9.60%)41 (12.7%) 2.164 (1.254, 3.733) ** 15 (4.64%)57 (17.6%) 2.183 (1.090, 4.374) * 11 (3.41%)61 (18.9%)1.151(0.551, 2.405)21 (6.50%)51 (15.8%) 3.033 (1.607, 5.726) **
Lower65 (20.1%)186 (57.6%)Reference27 (8.36%)224 (69.3%)Reference34 (10.5%)217 (67.2%)Reference30 (9.29%)221 (68.4%)Reference
Family Income
More than 20,000 INR(monthly)23 (7.12%)31 (9.60%) 1.992 (1.091, 3.640) * 13 (4.02%)41 (12.7%) 2.624 (1.260, 5.463) ** 10 (3.10%)44 (13.6%)1.519(0.701, 3.292)15 (4.64%)39 (12.1%) 2.489 (1.247, 4.969) **
Less than 20,000 INR(monthly)73 (22.6%)196 (60.7%)Reference29 (8.98%)240 (74.3%)Reference35 (10.8%)234 (72.4%)Reference36 (11.1%)233 (72.1%)Reference
CKD Stage
Stage III27 (8.36%)84 (26.0%)0.811(0.424, 1.551)8 (2.48%)103 (31.9%) 0.292 (0.119, 0.717) * 16 (4.95%)95 (29.4%)1.537(0.624, 3.787)16 (4.95%)95 (29.4%)0.968(0.431, 2.177)
Stage II46 (14.2%)85 (26.3%)1.365(0.748, 2.491)17 (5.26%)114 (35.3%)0.561(0.268, 1.175)21 (6.50%)110 (34.1%)1.742(0.732, 4.143)23 (7.12%)108 (33.4%)1.225(0.572, 2.620)
Stage I23 (7.12%)58 (18.0%)Reference17 (5.26%)64 (19.8%)Reference8 (2.48%)73 (22.6%)Reference12 (3.72%)69 (21.4%)Reference
HTN Stage
Stage I HTN19 (5.88%)57 (17.6%)0.926(0.469, 1.829)11 (3.41%)65 (20.1%)1.400(0.572, 3.424)11 (3.41%)65 (20.1%)1.159(0.488, 2.750)11 (3.41%)65 (20.1%)1.064(0.454, 2.494)
Stage II HTN20 (6.19%)36 (11.1%)1.543(0.765, 3.113)10 (3.10%)46 (14.2%)1.798(0.712, 4.544)10 (3.10%)46 (14.2%)1.489(0.607, 3.654)11 (3.41%)45 (13.9%)1.537(0.645, 3.659)
Prehypertension30 (9.29%)59 (18.3%)1.412(0.758, 2.630)10 (3.10%)79 (24.5%)1.047(0.422, 2.596)11 (3.41%)78 (24.1%)0.965(0.409, 2.278)15 (4.64%)74 (22.9%)1.274(0.578, 2.811)
Normal27 (8.36%)75 (23.2%)Reference11 (3.41%)91 (28.2%)Reference13 (4.02%)89 (27.6%)Reference14 (4.33%)88 (27.2%)Reference
BMI Categories
Overweight29 (8.98%)91 (28.2%)0.623(0.358, 1.084)16 (4.95%)104 (32.2%)0.755(0.376, 1.518)18 (5.57%)102 (31.6%)1.031(0.513, 2.073)12 (3.72%)108 (33.4%)0.424(0.204, 0.881)
Obese23 (7.12%)50 (15.5%)0.899(0.487, 1.660)4 (1.24%)69 (21.4%) 0.285 (0.094, 0.861) * 8 (2.48%)65 (20.1%)0.719(0.298, 1.735)12 (3.72%)61 (18.9%)0.750(0.354, 1.589)
Normal44 (13.6%)86 (26.6%)Reference22 (6.81%)108 (33.4%)Reference19 (5.88%)111 (34.4%)Reference27 (8.36%)103 (31.9%)Reference
Co-morbidities
Yes35 (10.8%)79 (24.5%)1.075(0.654, 1.767)18 (5.57%)96 (29.7%)1.445(0.748, 2.794)15 (4.64%)99 (30.7%)0.904(0.464, 1.761)21 (6.50%)93 (28.8%)1.347(0.731, 2.483)
No61 (18.9%)148 (45.8%)Reference24 (7.43%)185 (57.3%)Reference30 (9.29%)179 (55.4%)Reference30 (9.29%)179 (55.4%)Reference
Duration of Diabetes
More than 10 years51 (15.8%)104 (32.2%)1.340(0.831, 2.163)21 (6.50%)134 (41.5%)1.097(0.574, 2.098)22 (6.81%)133 (41.2%)1.043(0.555, 1.958)26 (8.05%)129 (39.9%)1.153(0.634, 2.097)
Less than 10 years45 (13.9%)123 (38.1%)Reference21 (6.50%)147 (45.5%)Reference23 (7.12%)145 (44.9%)Reference25 (7.74%)143 (44.3%)Reference
Glycemic Control
Poor (HbA1c ≥ 7)69 (21.4%)162 (50.2%)0.975(0.574, 1.657)32 (9.91%)199 (61.6%)0.758(0.356, 1.614)34 (10.5%)197 (61.0%)0.787(0.380, 1.629)39 (12.1%)192 (59.4%)0.739(0.368, 1.484)
Good (HbA1c < 7)27 (8.36%)65 (20.1%)Reference10 (3.10%)82 (25.4%)Reference11 (3.41%)81 (25.1%)Reference12 (3.72%)80 (24.8%)Reference
Duration of HTN #
More than 5 years14 (10.60%)37 (27.81%)0.75 (0.35, 1.63)12 (9.09%)40 (30.30%)0.857(0.379, 1.935)8 (6.06%)43 (32.57%)0.890(0.344, 2.300)4 (3.03%)47 (65.60%)0.899(0.249, 3.241)
Less than 5 years27 (20.45%)54 (40.90%)Reference21 (15.90%)60 (45.45%)Reference14 (10.60%)67 (50.75%)Reference7 (5.30%)74 (56.06%)Reference

C: Correct response; IC: Incorrect response; INR: Indian National Rupees; CKD: Chronic Kidney Disease; HTN: Hypertension; BMI: Body Mass Index. Bold data represents significant value. * Represents significant findings (p < 0.05); ** Represents significant findings (p <0.001); # Analysis based on patients belongs to stage I and stage II HTN class only.

4. Discussion

It is evident from the literature that burden of diabetes is continuously increasing, which will contribute to the rising prevalence of CKD globally [9,10]. Published literature revealed that CKD can be reversible and preventable from its progression to end-stage kidney disease if it is diagnosed at an early stage [21,22]. Previous studies found poor knowledge of CKD among the general public, however, limited studies have assessed the knowledge of CKD among high-risk patients [23,24,25]. This was the first cross-sectional study assessing the knowledge of CKD among a high-risk population with diabetes and hypertension as co-morbid conditions. The current study revealed poor knowledge of CKD among these patients. Less than a quarter of the patients had good knowledge of CKD (knowledge score ≥ 4). Poor knowledge of CKD was also found in other studies conducted around the globe [24,35]. In this study, only one-third (33%) of the patients identified hypertension and diabetes as risk factors of CKD. A cross-sectional survey conducted among the non-CKD Malaysian population found half of the population (51.2%) to be aware of diabetes and hypertension as risk factors of CKD [24]. Variation in risk factor awareness could be due to the higher education level among the Malaysian population, as all (100%) the respondents were literate and 78.3% of the respondents had secondary or above secondary education levels [24]. Similarly, a cross-sectional telephonic survey among community-dwelling adults also revealed poor awareness of CKD and less than half of the population were aware of diabetes or hypertension as risk factors of CKD [35]. A lack of awareness about common risk factors like hypertension and diabetes is raising the alarm for the need for further action. Furthermore, this population is less likely to get proper screening, adhere to prescribed medication regimens, or take part in decision making, which may ultimately contribute to the rising prevalence of CKD and further progression of CKD to its end stages. Our study also found that patients who had a family history of diabetes or poor glycemic control were more likely to have a higher knowledge of CKD, including the risk factors. Higher knowledge among these patients could be possibly due to poor health status (uncontrolled diabetes), or patients who have heard of CKD are more likely to have better knowledge [36]. A study by Fezeu et al. [37] also concluded that patients whose relatives had a chronic condition are generally more aware (p < 0.001) of the disease. Patients belonging to the middle class or having higher family income were also found to have a higher knowledge of CKD. Family income is considered to be an important factor affecting the quality of life among non-dialysis CKD patients [38]. Previous studies also suggested that low income is associated with a higher prevalence of chronic conditions [39]. No significant difference in knowledge score was observed among respondents stratified according to CKD stages, hypertension stages, BMI, age, gender, and co-morbidities. The findings of Finkelstein et al. [40] also found no impact of age, gender, and disease on patients’ knowledge of CKD. However, they found that knowledge of CKD improved significantly as the CKD stage progressed, particularly in stage 5 CKD. Our result was contrary to that, as we did not find any significant improvement in knowledge on the basis of CKD stages. A possible reason for this could be due to the inclusion of non-dialysis (stage I to III CKD) patients only. The study should be interpreted in light of certain limitations. Firstly, the findings of the study cannot be generalized to the entire CKD population, as the study was comprised only of patients from a single center. Secondly, the study was limited in regard to the selection of participants (selection bias); to overcome this, we consecutively selected the participants. There were several notable strengths of this study. Firstly, the study included T2DM and hypertensive patients and performed stratification based on CKD and hypertension stages. Secondly, the knowledge level was correlated with diabetes and hypertension status. The present study also highlighted the needs of CKD education among T2DM and hypertensive patients, since a lack of knowledge about these risk factors was reflected in the study that may have resulted in late referral to the nephrologist and poor participation in the decision-making process. Future studies are warranted to assess the CKD knowledge in a large population-based sample and to frame a CKD awareness model for high-risk patients as well as the general population in order to promote earlier diagnosis, better treatment, and innovative care.

5. Conclusions

We found poor knowledge of kidney disease among T2DM and hypertensive Indian patients. The government should start a CKD awareness programme to deal with this devastating co-morbid condition, which would help in achieving cost-effective prevention.
  10 in total

1.  The proportion of chronic kidney disease and its associated factors among adult diabetic patients at Tibebe Ghion Specialized Hospital, Bahir Dar, Ethiopia.

Authors:  Daniel Tesfe; Mesert Adugna; Zelalem Mehari Nigussie; Alem Endeshaw Woldeyohanins; Zemene Demelash Kifle
Journal:  Metabol Open       Date:  2022-06-23

2.  Early detection of renal disease among truck drivers through organized screening.

Authors:  Rama Ravi; Georgi Abraham; Rajalakshmi Ravi; Milly Mathews; Rajeevalochana Partasarathy
Journal:  J Family Med Prim Care       Date:  2020-09-30

3.  Awareness of Chronic Kidney Disease, Medication, and Laboratory Investigation among Nephrology and Urology Patients of Quetta, Pakistan.

Authors:  Jahanzaib Ahmed; Saira Azhar; Noman Ul Haq; Sajjad Hussain; Anette Stájer; Edit Urbán; Márió Gajdács; Shazia Jamshed
Journal:  Int J Environ Res Public Health       Date:  2022-04-20       Impact factor: 4.614

4.  Prevalence of peripheral neuropathy and associated pain in patients with diabetes mellitus: Evidence from a cross-sectional study.

Authors:  Harveen Baxi; Anwar Habib; Md Sarfaraj Hussain; Salman Hussain; Kiran Dubey
Journal:  J Diabetes Metab Disord       Date:  2020-07-31

5.  Albuminuria Testing in Low-Income Setting.

Authors:  Megha Nataraj
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

Review 6.  Prevalence of Chronic Kidney Diseases in Patients with Diabetes Mellitus in the Middle East: A Systematic Review and Meta-Analysis.

Authors:  Abdallah Y Naser; Hassan Alwafi; Basil Alotaibi; Emad Salawati; Mohammed Samannodi; Zahra Alsairafi; Abeer F R Alanazi; Mohammad S Dairi
Journal:  Int J Endocrinol       Date:  2021-08-28       Impact factor: 3.257

7.  Chronic kidney disease awareness among the general population: tool validation and knowledge assessment in a developing country.

Authors:  Samar Younes; Nisreen Mourad; Jihan Safwan; Mariam Dabbous; Mohamad Rahal; Marah Al Nabulsi; Fouad Sakr
Journal:  BMC Nephrol       Date:  2022-07-26       Impact factor: 2.585

Review 8.  A Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease.

Authors:  Chongbin Liu; Ming Yang; Li Li; Shilu Luo; Jinfei Yang; Chenrui Li; Huafeng Liu; Lin Sun
Journal:  Front Physiol       Date:  2022-07-06       Impact factor: 4.755

9.  Knowledge of chronic kidney disease among undergraduate and postgraduate students in a public university in Klang Valley, Malaysia: A cross sectional study.

Authors:  Lean Cheong Loo; Kah Wei Ong; Aida Khalisha Ahmad Nidzwal; Muhammad Helmi Razali; Nizal Ahmad; Azlinah Naim; Faiz Daud; Abdul Halim Abdul Gafor; Norfazilah Ahmad
Journal:  PLoS One       Date:  2022-09-23       Impact factor: 3.752

10.  Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.

Authors:  Hongwei Cao; Tao Liu; Li Wang; Qiuhe Ji
Journal:  Diabetes Obes Metab       Date:  2022-06-06       Impact factor: 6.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.